{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:01:48Z","timestamp":1784872908163,"version":"3.55.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["212167"],"award-info":[{"award-number":["212167"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV pretreatment drug resistance (PDR) is an increasing global concern affecting transmitted resistance and first-line therapy effectiveness. Colombia lacks recent nationwide data on transmitted resistance. Although national guidelines recommend second-generation integrase strand transfer inhibitors (INSTIs) as preferred first-line options, efavirenz remains widely prescribed. This study estimated HIV PDR prevalence in Colombia to inform best practices for first-line antiretroviral therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional, nationally representative survey using next-generation sequencing of plasma samples from individuals initiating or reinitiating first-line antiretroviral treatment across Colombia\u2019s natural regions, stratified by national HIV prevalence data. Samples collected between 2021 and 2023 were analysed for drug resistance mutations (DRMs) following World Health Organization recommendations and interpreted using Stanford HIVdb v9.6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 483 participants were enrolled; 98.3% had HIV-1 subtype B, 94.3% were Colombian nationals, the median age was 32.5\u2005years (standard deviation\u200a\u00b1\u200a10.8), 19.9% were female, and 27.5% had CD4 counts &amp;lt;200 cells\/mm\u00b3. Median HIV-1 RNA was 54\u200a754\u2005copies\/mL (interquartile range [IQR]: 15\u200a685\u2013166\u200a000); 6.2% were treatment reinitiators. The wild-type virus was identified in 61.7%. Overall, PDR prevalence was 20.3% (95% confidence interval [CI] 16.8\u201324.2), driven mainly by non-nucleoside reverse transcriptase inhibitor resistance (NNRTI) (18.0%, 95% CI 14.7\u201321.7), with K103N as the most frequent DRM. INSTI DRMs were rare (2.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This nationwide survey demonstrates alarmingly high NNRTI resistance but minimal INSTI resistance, underscoring the urgent need to phase out efavirenz-based regimens. Strengthening access to affordable second-generation-based therapies and enhancing prescriber education are critical to sustaining treatment efficacy and preventing further transmission of resistant HIV strains.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf444","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:56:38Z","timestamp":1764075398000},"source":"Crossref","is-referenced-by-count":0,"title":["National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0959-8593","authenticated-orcid":false,"given":"Ernesto","family":"Mart\u00ednez-Buitrago","sequence":"first","affiliation":[{"name":"Fundaci\u00f3n REVIVA, Red de VIH del Valle del Cauca , Cali ,","place":["Colombia"]},{"name":"Department of Internal Medicine, Universidad del Valle , Cali ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s Felipe","family":"Zapata-Mar\u00edn","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n REVIVA, Red de VIH del Valle del Cauca , Cali ,","place":["Colombia"]},{"name":"Corporaci\u00f3n de Lucha Contra el SIDA , Cali ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Consuelo","family":"Rubiano","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n REVIVA, Red de VIH del Valle del Cauca , Cali ,","place":["Colombia"]},{"name":"Fundaci\u00f3n Casa GAMI , Cali ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz Marina","family":"San\u0303udo","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n REVIVA, Red de VIH del Valle del Cauca , Cali ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mill\u00e1n","family":"On\u0303ate","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n REVIVA, Red de VIH del Valle del Cauca , Cali ,","place":["Colombia"]},{"name":"Clinica Imbanaco , Cali ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lenis","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n REVIVA, Red de VIH del Valle del Cauca , Cali ,","place":["Colombia"]},{"name":"Recuperar IPS , Cali ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Fernando","family":"Garci\u0301a-G\u00f3ez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n REVIVA, Red de VIH del Valle del Cauca , Cali ,","place":["Colombia"]},{"name":"Hospital Universitario Fundaci\u00f3n Valle del Lili , Cali ,","place":["Colombia"]},{"name":"Universidad ICESI , Cali ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Eli\u00e9cer","family":"A\u0301lvarez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n REVIVA, Red de VIH del Valle del Cauca , Cali ,","place":["Colombia"]},{"name":"Department of Internal Medicine, Universidad del Valle , Cali ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Garc\u00eda-Morales","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Enfermedades Infecciosas del Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas , Ciudad de M\u00e9xico ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Mat\u00edas-Florentino","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Enfermedades Infecciosas del Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas , Ciudad de M\u00e9xico ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"A\u0301vila-Ri\u0301os","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Enfermedades Infecciosas del Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas , Ciudad de M\u00e9xico ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"2026072401114645900_dkaf444-B1","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1016\/j.ijid.2009.05.006","article-title":"Antiretroviral drug resistance in HIV-infected patients in Colombia","volume":"14","author":"DiazGranados","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2026072401114645900_dkaf444-B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0123-9392(13)70044-4","article-title":"Transmitted HIV resistance in ART-Na\u00efve patients in Cali, Colombia, 2010","volume":"17","author":"Galindo-Orrego","year":"2013","journal-title":"Infectio"},{"key":"2026072401114645900_dkaf444-B3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.22354\/in.v22i2.713","article-title":"Transmitted HIV-1 resistance in never exposed to antiretroviral therapy patients, Cali-Colombia 2008-2015","volume":"22","author":"Coral-Orbes","year":"2018","journal-title":"Infectio"},{"key":"2026072401114645900_dkaf444-B4"},{"key":"2026072401114645900_dkaf444-B5","author":"Fondo Colombiano de Enfermedades de Alto Costo, Cuenta de Alto Costo (CAC)"},{"key":"2026072401114645900_dkaf444-B6","author":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica (GPC) basada en la evidencia cient\u00edfica para la atenci\u00f3n de la infecci\u00f3n por VIH\/SIDA en personas adultas, gestantes y adolescentes"},{"key":"2026072401114645900_dkaf444-B7"},{"key":"2026072401114645900_dkaf444-B8"},{"key":"2026072401114645900_dkaf444-B9","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2026072401114645900_dkaf444-B10","author":"Fondo Colombiano de Enfermedades de Alto Costo, Cuenta de Alto Costo (CAC)"},{"key":"2026072401114645900_dkaf444-B11","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1016\/S2352-3018(16)30119-9","article-title":"Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey","volume":"3","author":"\u00c1vila-R\u00edos","year":"2016","journal-title":"Lancet HIV"},{"key":"2026072401114645900_dkaf444-B12","doi-asserted-by":"publisher","first-page":"e00105-18","DOI":"10.1128\/JCM.00105-18","article-title":"Comparison of an in vitro diagnostic next-generation sequencing assay with Sanger sequencing for HIV-1 genotypic resistance testing","volume":"56","author":"Tzou","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2026072401114645900_dkaf444-B13","author":"DANE"},{"key":"2026072401114645900_dkaf444-B14","author":"Aseguramiento al sistema general de salud"},{"key":"2026072401114645900_dkaf444-B15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/v16020239","article-title":"HIV-1 drug resistance detected by next-generation sequencing among ART-Na\u00efve individuals: a systematic review and meta-analysis","volume":"16","author":"Ouyang","year":"2024","journal-title":"Viruses"},{"key":"2026072401114645900_dkaf444-B16","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/jac\/dkx232","article-title":"RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-na\u00efve patients","volume":"72","author":"Alidjinou","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114645900_dkaf444-B17","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/jmv.24872","article-title":"Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples","volume":"89","author":"Trabaud","year":"2017","journal-title":"J Med Virol"},{"key":"2026072401114645900_dkaf444-B18","doi-asserted-by":"publisher","first-page":"21846","DOI":"10.7448\/IAS.20.1.21846","article-title":"Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014","volume":"20","author":"Moscona","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2026072401114645900_dkaf444-B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.virusres.2016.10.019","article-title":"Deep sequencing for HIV-1 clinical management","volume":"239","author":"Casadell\u00e0","year":"2017","journal-title":"Virus Res"},{"key":"2026072401114645900_dkaf444-B20","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.1038\/s41598-018-25888-6","article-title":"Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing","volume":"8","author":"Telele","year":"2018","journal-title":"Sci Rep"},{"key":"2026072401114645900_dkaf444-B21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/v12070694","article-title":"Multi-laboratory comparison of next-generation to Sanger-based sequencing for HIV-1 drug resistance genotyping","volume":"12","author":"Parkin","year":"2020","journal-title":"Viruses"},{"key":"2026072401114645900_dkaf444-B22","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/jac\/dkac430","article-title":"Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1","volume":"78","author":"Balakrishna","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114645900_dkaf444-B23","first-page":"69","article-title":"Genetic barriers to resistance and impact on clinical response","volume":"7","author":"Luber","year":"2005","journal-title":"MedGenMed"},{"key":"2026072401114645900_dkaf444-B24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/QAD.0b013e3282f3cc35","article-title":"Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA","volume":"22","author":"Bannister","year":"2008","journal-title":"AIDS"},{"key":"2026072401114645900_dkaf444-B25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1468-1293.2011.00943.x","article-title":"The rate of accumulation of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI","volume":"13","author":"Cozzi-Lepri","year":"2012","journal-title":"HIV Med"},{"key":"2026072401114645900_dkaf444-B26","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"2026072401114645900_dkaf444-B27"},{"key":"2026072401114645900_dkaf444-B28","doi-asserted-by":"publisher","first-page":"e25429","DOI":"10.1002\/jia2.25429","article-title":"High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016","volume":"22","author":"Gir\u00f3n-Callejas","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"2026072401114645900_dkaf444-B29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/jac\/dkw445","article-title":"Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15","volume":"72","author":"Bissio","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114645900_dkaf444-B30","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/pathogens10121587","article-title":"HIV pretreatment drug resistance trends in Mexico city, 2017-2020","volume":"10","author":"Garc\u00eda-Morales","year":"2021","journal-title":"Pathogens"},{"key":"2026072401114645900_dkaf444-B31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1089\/aid.2023.0083","article-title":"Pretreatment HIV-1 resistance in Argentina: results from the second surveillance study following World Health Organization guidelines (2019)","volume":"40","author":"Laufer","year":"2024","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026072401114645900_dkaf444-B32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/v15020490","article-title":"HIV drug resistance in adults initiating or reinitiating antiretroviral therapy in Uruguay-results of a nationally representative survey, 2018-2019","volume":"15","author":"Flieller","year":"2023","journal-title":"Viruses"},{"key":"2026072401114645900_dkaf444-B33","doi-asserted-by":"publisher","first-page":"ofac580","DOI":"10.1093\/ofid\/ofac580","article-title":"High level of pretreatment and acquired human immunodeficiency virus drug resistance in El Salvador: a nationally representative survey, 2018-2019","volume":"9","author":"Gir\u00f3n-Callejas","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026072401114645900_dkaf444-B34","doi-asserted-by":"publisher","first-page":"e0158560","DOI":"10.1371\/journal.pone.0158560","article-title":"Surveillance of HIV transmitted drug resistance in Latin America and the Caribbean: a systematic review and meta-analysis","volume":"11","author":"Avila-Rios","year":"2016","journal-title":"PLoS One"},{"key":"2026072401114645900_dkaf444-B35"},{"key":"2026072401114645900_dkaf444-B36","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/jac\/dkae087","article-title":"Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and Southeast Asian countries","volume":"79","author":"Aghokeng","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114645900_dkaf444-B37","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/cid\/ciac972","article-title":"Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe","volume":"76","author":"de Salazar","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026072401114645900_dkaf444-B38","doi-asserted-by":"publisher","first-page":"107294","DOI":"10.1016\/j.ijantimicag.2024.107294","article-title":"Beware of resistance to 2nd-generation integrase inhibitors: a systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations","volume":"64","author":"Liu","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2026072401114645900_dkaf444-B39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/jac\/dkz502","article-title":"Pretreatment HIV drug resistance spread within transmission clusters in Mexico city","volume":"75","author":"Mat\u00edas-Florentino","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"2026072401114645900_dkaf444-B40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.22354\/in.v23i1.764","article-title":"Identificaci\u00f3n de mutaciones asociadas con resistencia a inhibidores de la transferencia de cadena de integrasa en pacientes VIH-1 positivos naive para tratamiento antieretroviral en Medell\u00edn, Colombia","volume":"23","author":"Vanegas-Ot\u00e1lvaro","year":"2019","journal-title":"Infectio"},{"key":"2026072401114645900_dkaf444-B41","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114645900_dkaf444-B42","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/infdis\/jiab413","article-title":"Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients","volume":"225","author":"Palich","year":"2022","journal-title":"J Infect Dis"},{"key":"2026072401114645900_dkaf444-B43","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/jac\/dkae164","article-title":"The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen type","volume":"79","author":"Teyssou","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114645900_dkaf444-B44","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3390\/v16111697","article-title":"Archived HIV-1 drug resistance mutations: role of proviral HIV-1 DNA genotype for the management of virological responder people living with HIV","volume":"16","author":"Campagna","year":"2024","journal-title":"Viruses"},{"key":"2026072401114645900_dkaf444-B45","doi-asserted-by":"publisher","first-page":"102779","DOI":"10.1016\/j.ebiom.2020.102779","article-title":"Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical randomization to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)","volume":"55","author":"De Miguel","year":"2020","journal-title":"EBioMedicine"},{"key":"2026072401114645900_dkaf444-B46","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3390\/v16091392","article-title":"Treatment management challenges in Na\u00efve and experienced HIV-1-infected individuals carrying the M184V mutation","volume":"16","author":"Mimtsoudis","year":"2024","journal-title":"Viruses"},{"key":"2026072401114645900_dkaf444-B47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/jac\/dkae007","article-title":"Use of genotypic HIV DNA testing: a DELPHI-type consensus","volume":"79","author":"Andre-Garnier","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114645900_dkaf444-B48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/cid\/ciaf100","article-title":"Dolutegravir\/lamivudine for maintenance of virological suppression in persons with historical suspected or confirmed resistance to lamivudine: week 48 results of a single-arm, open-label, multicenter, phase IIa clinical trial","volume":"81","author":"De Miguel","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026072401114645900_dkaf444-B49"},{"key":"2026072401114645900_dkaf444-B50","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","volume":"10","author":"Loosli","year":"2023","journal-title":"Lancet HIV"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf444\/66058901\/dkaf444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf444\/66058901\/dkaf444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:11:54Z","timestamp":1784869914000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf444\/8388009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf444","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,22]]},"article-number":"dkaf444"}}